X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (679) 679
Publication (87) 87
Newspaper Article (12) 12
Book Review (9) 9
Dissertation (3) 3
Newsletter (3) 3
Book / eBook (1) 1
Book Chapter (1) 1
Data Set (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (341) 341
humans (338) 338
animals (318) 318
phosphorylation (174) 174
kinases (168) 168
mice (152) 152
oncology (140) 140
signal transduction (140) 140
apoptosis (119) 119
male (112) 112
proteins (110) 110
biochemistry & molecular biology (108) 108
cells, cultured (106) 106
cell biology (104) 104
expression (104) 104
rats (102) 102
research (99) 99
cancer (98) 98
signal transduction - drug effects (98) 98
activation (95) 95
female (91) 91
cell line, tumor (90) 90
mitogen-activated protein kinase 1 - metabolism (87) 87
gene expression (83) 83
mitogen-activated protein kinase 3 - metabolism (71) 71
enzyme inhibitors - pharmacology (70) 70
extracellular signal-regulated kinase (66) 66
mitogen-activated protein kinases - metabolism (66) 66
phosphorylation - drug effects (66) 66
rodents (60) 60
extracellular signal-regulated map kinases - metabolism (59) 59
pharmacology & pharmacy (59) 59
article (57) 57
map kinase (57) 57
physiological aspects (57) 57
protein kinases (56) 56
research article (56) 56
cell proliferation (55) 55
endocrinology & metabolism (55) 55
blotting, western (54) 54
medicine (53) 53
apoptosis - drug effects (52) 52
inflammation (52) 52
cell proliferation - drug effects (51) 51
gene-expression (51) 51
kinase kinase-1/2 inhibitor (51) 51
enzyme activation (50) 50
genetic aspects (50) 50
health aspects (50) 50
map kinase signaling system - drug effects (50) 50
physiology (50) 50
cell line (49) 49
activated protein-kinase (48) 48
in-vitro (48) 48
protein kinase inhibitors - pharmacology (48) 48
proliferation (46) 46
tumors (46) 46
cells (45) 45
medicine, research & experimental (44) 44
nf-kappa-b (44) 44
dose-response relationship, drug (43) 43
p38 mitogen-activated protein kinases - metabolism (43) 43
immunology (42) 42
in-vivo (42) 42
science (42) 42
biology (41) 41
multidisciplinary sciences (41) 41
studies (41) 41
growth (40) 40
inhibition (40) 40
pathway (39) 39
phosphatidylinositol 3-kinases - metabolism (39) 39
enzyme activation - drug effects (38) 38
care and treatment (37) 37
metastasis (37) 37
proto-oncogene proteins c-akt - metabolism (37) 37
signal transduction - physiology (37) 37
cytokines (36) 36
flavonoids - pharmacology (36) 36
oxidative stress (36) 36
rats, sprague-dawley (36) 36
cell cycle (35) 35
cell growth (35) 35
antineoplastic agents - pharmacology (34) 34
transfection (34) 34
mitogen-activated protein kinase 3 (33) 33
review (33) 33
time factors (33) 33
analysis (31) 31
hematology (31) 31
angiogenesis (30) 30
reverse transcriptase polymerase chain reaction (30) 30
up-regulation (30) 30
breast cancer (29) 29
mitogens (29) 29
mutation (29) 29
chemotherapy (28) 28
neurosciences (28) 28
pyridines - pharmacology (28) 28
signaling (28) 28
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Proceedings of the National Academy of Sciences of the United States of America, ISSN 0027-8424, 8/2010, Volume 107, Issue 33, pp. 14903 - 14908
Tumors with mutant BRAF and some with mutant RAS are dependent upon ERK signaling for proliferation, and their growth is suppressed by MAPK/ERK kinase (MEK)... 
Tumor cell line | Phosphorylation | Cell growth | Negative feedback | Genes | Cell lines | Melanoma | Genetic mutation | Tumors | Cancer | LUNG-CANCER | APOPTOSIS | KINASE KINASE-1/2 INHIBITOR | ACTIVATION | PATHWAY | MULTIDISCIPLINARY SCIENCES | IN-VIVO | B-RAF | MUTATIONS | MEK INHIBITORS | ADVANCED CANCERS | Diphenylamine - pharmacology | Oligonucleotide Array Sequence Analysis | Apoptosis - drug effects | Humans | Gene Expression Profiling | Extracellular Signal-Regulated MAP Kinases - metabolism | Diphenylamine - analogs & derivatives | Mitogen-Activated Protein Kinase Kinases - metabolism | Indoles - pharmacology | Benzamides - pharmacology | G1 Phase - genetics | Gene Expression Regulation, Neoplastic - drug effects | Phosphorylation - drug effects | Proto-Oncogene Proteins B-raf - metabolism | Mitogen-Activated Protein Kinase Kinases - antagonists & inhibitors | Reverse Transcriptase Polymerase Chain Reaction | Sulfonamides - pharmacology | Blotting, Western | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Vemurafenib | Signal Transduction - drug effects | Proto-Oncogene Proteins B-raf - genetics | Cell Line, Tumor | Cell Proliferation - drug effects | Mutation | Amino Acid Substitution | Cell proliferation | Development and progression | Cellular signal transduction | Genetic aspects | Pharmacology | Research | Drug therapy | Index Medicus | Biological Sciences
Journal Article
Nature Medicine, ISSN 1078-8956, 10/2012, Volume 18, Issue 10, pp. 1503 - 1510
Journal Article
Cancer Research, ISSN 0008-5472, 11/2010, Volume 70, Issue 21, pp. 8736 - 8747
Journal Article
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2013, Volume 14, Issue 8, pp. 733 - 740
Summary Background Patients with metastatic melanoma, 50% of whose tumours harbour a BRAF mutation, have a poor prognosis. Selumetinib, a MEK1/2 inhibitor, has... 
Hematology, Oncology and Palliative Medicine | CELL LUNG-CANCER | TRIAL | KINASE KINASE-1/2 INHIBITOR | MULTICENTER | ONCOLOGY | ORAL MEK INHIBITOR | IMPROVED SURVIVAL | INHIBITOR AZD6244 ARRY-142886 | OPEN-LABEL | MUTATIONS | VEMURAFENIB | Dacarbazine - adverse effects | Skin Neoplasms - drug therapy | Humans | Middle Aged | Male | Antineoplastic Agents, Alkylating - administration & dosage | Skin Neoplasms - enzymology | Benzimidazoles - administration & dosage | Time Factors | DNA Mutational Analysis | Brazil | Proto-Oncogene Proteins B-raf - metabolism | Dacarbazine - administration & dosage | Genetic Predisposition to Disease | Neoplasms, Unknown Primary - genetics | Europe | Logistic Models | Antineoplastic Agents, Alkylating - therapeutic use | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Protein Kinase Inhibitors - administration & dosage | Phenotype | Mutation | Antineoplastic Agents, Alkylating - adverse effects | Melanoma - mortality | Dacarbazine - therapeutic use | United States | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Melanoma - enzymology | Neoplasms, Unknown Primary - enzymology | Melanoma - genetics | Skin Neoplasms - mortality | Adult | Female | Skin Neoplasms - pathology | Neoplasms, Unknown Primary - drug therapy | Double-Blind Method | Drug Administration Schedule | Kaplan-Meier Estimate | Proportional Hazards Models | Treatment Outcome | Neoplasms, Unknown Primary - mortality | Melanoma - secondary | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Proto-Oncogene Proteins B-raf - genetics | Melanoma - drug therapy | Skin Neoplasms - genetics | Aged | Neoplasms, Unknown Primary - pathology | Care and treatment | Chemotherapy | Gene mutations | Analysis | Melanoma | Metastasis | Cancer
Journal Article
Journal Article
Thyroid, ISSN 1050-7256, 08/2008, Volume 18, Issue 8, pp. 853 - 864
Background: We recently demonstrated inhibition of thyroid cancer cells by the MEK inhibitor CI-1040. The objective of this study was to use a potent... 
REARRANGEMENT | KINASE KINASE-1/2 INHIBITOR | THERAPY | BRAF MUTATION | GROWTH | ENDOCRINOLOGY & METABOLISM | SENSITIVITY | PROLIFERATION | MECHANISMS | PAPILLARY | TUMORS | Original Studies, Reviews and Scholarly Dialog
Journal Article
Investigational New Drugs, ISSN 0167-6997, 10/2011, Volume 29, Issue 5, pp. 1021 - 1028
Objectives To assess the efficacy and safety of the MEK1/2 inhibitor AZD6244 (ARRY-142886) in patients with metastatic colorectal cancer who had failed one or... 
Medicine & Public Health | AZD6244 | Colorectal cancer | Oncology | Clinical trial | Phase II | MEK inhibitor | Pharmacology/Toxicology | KINASE KINASE-1/2 INHIBITOR | FLUOROURACIL PLUS LEUCOVORIN | OXALIPLATIN | ORAL CAPECITABINE | POTENT | THERAPY | ONCOLOGY | PHARMACOLOGY & PHARMACY | Demography | Capecitabine | Humans | Middle Aged | Male | Antineoplastic Agents - therapeutic use | Protein Kinase Inhibitors - adverse effects | Dose-Response Relationship, Drug | Fluorouracil - therapeutic use | Mitogen-Activated Protein Kinase Kinases - metabolism | Deoxycytidine - therapeutic use | Fluorouracil - administration & dosage | Benzimidazoles - administration & dosage | Fluorouracil - adverse effects | Antineoplastic Agents - adverse effects | Colorectal Neoplasms - drug therapy | Treatment Failure | Aged, 80 and over | Adult | Deoxycytidine - adverse effects | Female | Benzimidazoles - adverse effects | Benzimidazoles - therapeutic use | Colorectal Neoplasms - enzymology | Fluorouracil - analogs & derivatives | Deoxycytidine - administration & dosage | Mitogen-Activated Protein Kinase Kinases - antagonists & inhibitors | Proportional Hazards Models | Disease Progression | Disease-Free Survival | Protein Kinase Inhibitors - administration & dosage | Protein Kinase Inhibitors - therapeutic use | Aged | Deoxycytidine - analogs & derivatives | Antimitotic agents | Complications and side effects | Dosage and administration | Research | Antineoplastic agents | Drug therapy | Studies | Clinical trials | Pharmacology | Inhibitor drugs
Journal Article